|Security||TIF / Tiffany & Co. (886547108)|
|Common Stock Shares Outstanding||124,500,000 shares (as of 2018-01-31)|
Stock Insider Trading (from SEC Form 4)
Tiffany & Co. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
TIF / Tiffany & Co. insiders include Cumenal Frederic, Erceg Mark J, MARQUIS CHARLES K., TRIAN FUND MANAGEMENT, L.P., Galtie Philippe, NICOLETTI RALPH J, MAY PETER W, Davey Andrea, Qatar Investment Authority, and Qatar Holding USA LLC Trapani Francesco, FARAH ROGER N, BERGER GROSS VICTORIA, Cloud Pamela H, BRAVO ROSE MARIE, LILLIE JAMES E, De Winter Jennifer, NAGGIAR CAROLINE D, Hart Andrew W., Barresi John S, FISH LAWRENCE K, COSTLEY GARY E, Bellaiche Jean-Marc, Harlan Leigh M., KOHNSTAMM ABBY F, Singer Robert S, KOWALSKI MICHAEL JOSEPH, Bogliolo Alessandro, PETTERSON JOHN S, Rinaldo Michael D, Koback-Pursel Gretchen, SHUTZER WILLIAM A, .
NAGGIAR CAROLINE D
FARAH ROGER N
FISH LAWRENCE K
LILLIE JAMES E
Hart Andrew W.
Cloud Pamela H
Harlan Leigh M.
Rinaldo Michael D
KOWALSKI MICHAEL JOSEPH
Singer Robert S
COSTLEY GARY E
KOHNSTAMM ABBY F
Erceg Mark J
MARQUIS CHARLES K.
BRAVO ROSE MARIE
SHUTZER WILLIAM A
Qatar Holding USA LLC
Qatar Investment Authority
De Winter Jennifer
BERGER GROSS VICTORIA
Barresi John S
TRIAN FUND MANAGEMENT, L.P.
MAY PETER W
PETTERSON JOHN S
MAY PETER W
TRIAN FUND MANAGEMENT, L.P.
NICOLETTI RALPH J
Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||94.13||30,000||446,156||41,996,664|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||97.8709||5,000||416,156||40,729,562|
|4||FISH LAWRENCE K||S||D||98.5679||-6,000||34,511||3,401,677|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||98.4206||5,000||411,156||40,466,220|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||98.6719||5,000||406,156||40,076,184|
|4||FARAH ROGER N By Family Trust||P||I||97.6628||10,000||21,156||2,066,154|
|4||FISH LAWRENCE K||S||D||97.0243||-3,028||40,511||3,930,551|
|4||LILLIE JAMES E||P||D||96.5853||1,158||22,156||2,139,944|
|4||LILLIE JAMES E||P||D||95.857||3,842||20,998||2,012,805|
|4||Hart Andrew W.||S||D||96.4585||-776||10,065||970,855|
|4||Hart Andrew W.||F||D||97.97||-1,491||10,841|
|4||Hart Andrew W.||M||D||3,044||12,332|
|4||Harlan Leigh M.||F||D||97.97||-1,131||5,328|
|4||Harlan Leigh M.||M||D||2,297||6,459|
|4||Cloud Pamela H||F||D||97.97||-1,327||30,412|
|4||Cloud Pamela H||M||D||3,471||31,739|
|4||NAGGIAR CAROLINE D||F||D||97.97||-1,001||19,096|
|4||NAGGIAR CAROLINE D||M||D||2,617||20,097|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||95.8978||5,000||401,156||38,469,978|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||96.3325||5,000||396,156||38,162,698|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||97.3809||5,000||391,156||38,091,123|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||98.5548||5,000||386,156||38,057,527|
|4||Trapani Francesco By Argenta Holdings Sarl||P||I||98.399||5,000||381,156||37,505,369|
|4||LILLIE JAMES E||P||D||97.8099||5,000||17,156||1,678,027|
|4||Harlan Leigh M.||F||D||97.26||-42||4,162|
|4||Harlan Leigh M.||F||D||97.5749||-721||4,204|
|4||Harlan Leigh M.||M||D||37||4,925|
|4||Harlan Leigh M.||M||D||1,848||4,888|
|4||KOWALSKI MICHAEL JOSEPH||S||D||102.5287||-3,806||111,870||11,469,886|
|4||KOWALSKI MICHAEL JOSEPH||S||D||104.1083||-39,809||115,676||12,042,832|
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
Related News Stories
Tiffany & Co. is an overvalued company with a management team that does not understand its own target audience. (5-0)
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (826-0)
While most income investors are reaching for big yields right now, a small group of “hidden yield” stocks are quietly handing smart investors growing income streams plus annual returns of 12%, 27.1% and even 54% or more per year. (53-0)
Despite beating expectations for Q3 revenues and EPS, Atlassian shares sunk 7% in after-hours trading after reporting results. (38-0)
With its new talented CEO Alessandro Bogliolo and a new growth strategy, the company is set for another 5 to 10 years of market outperformance. (5-0)
as of ET